Security
RF Acquisition Corp II Right · RFAIR
RFAIRNASDAQRightCurrentCIK 2012807Updated Nov 14, 2026
RFAIR price & chart
Loading TradingView…
NASDAQ:RFAIR on TradingView ↗About the company
RFAI is a blank check company incorporated as a Cayman Islands corporation whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While RFAI may pursue an initial business combination target in any business, industry, or geographic location, it intends to focus its search on businesses in Asia within the deep technology sector, including artificial intelligence, quantum computing, and biotechnology. RFAI was incorporated in 2024 and is based in Singapore.
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G/A - filed by First Trust Capital Management L.P. regarding RF Acquisition Corp II
10-Q filing
SCHEDULE 13G/A - filed by MIZUHO FINANCIAL GROUP INC regarding RF Acquisition Corp II
SCHEDULE 13G/A - filed by BERKLEY W R CORP regarding RF Acquisition Corp II
425 filing
Show 5 more recent filings
Submission of Matters to a Vote of Security Holders · Other Events
Items 5.07, 8.01, 9.01
425 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders · Other Events
Items 1.01, 2.03, 5.03, 5.07, 8.01, 9.01
10-Q filing
DEF 14A filing
Financials
FY 2025 · USDSource
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| AssetsUSD | 123,463,751Source | — | 53,608,899Source | 122,255,599Source | 117,280,397Source | 53,131,825Source | 121,207,140Source | 297,673Source | 52,659,178Source | 120,078,338Source |
| Current assets: | ||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | 0Source |
| Assets, CurrentUSD | 591,342Source | — | 77,938Source | 669,721Source | 1,048,708Source | 240,151Source | 879,001Source | — | 401,800Source | 984,407Source |
| LIABILITIES AND EQUITY | ||||||||||
| LiabilitiesUSD | 4,551,764Source | — | 5,386,041Source | 4,400,481Source | 4,192,782Source | 5,193,394Source | 4,428,032Source | — | 4,994,449Source | 4,320,200Source |
| Stockholders’ equity: | ||||||||||
| Common Stock, Value, IssuedUSD | 352Source | — | 352Source | 352Source | 352Source | 352Source | 352Source | 308Source | 352Source | 352Source |
| Retained Earnings (Accumulated Deficit)USD | -3,960,774Source | — | -5,308,455Source | -3,731,112Source | -3,144,426Source | -4,953,595Source | -3,549,383Source | -60,420Source | -4,593,001Source | -3,336,145Source |
| Stockholders' Equity Attributable to ParentUSD | -3,960,422Source | -3,234,064Source | -5,308,103Source | -3,730,760Source | -3,144,074Source | -4,953,243Source | -3,549,031Source | -35,420Source | -4,592,649Source | -3,335,793Source |
| Liabilities and EquityUSD | 123,463,751Source | — | 53,608,899Source | 122,255,599Source | 117,280,397Source | 53,131,825Source | 121,207,140Source | 297,673Source | 52,659,178Source | 120,078,338Source |
| Current liabilities: | ||||||||||
| Liabilities, CurrentUSD | 526,764Source | — | 1,361,041Source | 375,481Source | 167,782Source | 1,168,394Source | 403,032Source | 333,093Source | 969,449Source | 295,200Source |
| Additional Financial Items | ||||||||||
| Accrued Liabilities, CurrentUSD | 223,214Source | — | 941,381Source | 101,931Source | 29,232Source | 779,119Source | 159,482Source | 3,800Source | 635,174Source | 81,650Source |
| Additional Paid in Capital | — | — | — | — | — | — | — | —Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 1,056,869Source | 1,422,951Source | 104,427Source | 1,076,010Source | 93,702Source | 1,020,970Source | 3,367,296Source | 3,157,131Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -267,646Source | -146,448Source | -561,403Source | -89,501Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -180,000Source | — | 71,460,705Source | -115,575,000Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 145,000Source | — | -71,520,705Source | 116,623,287Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 562,225Source | 986,256Source | 10,191Source | 626,321Source | 34,737Source | 812,338Source | 337,383Source | 958,786Source |
| Additional Financial Items | ||||||||||
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,056,869Source | 1,422,951Source | 104,427Source | 1,076,010Source | 93,702Source | 1,020,970Source | 3,367,296Source | 3,157,131Source |
| Operating Costs and ExpensesUSD | — | — | 229,662Source | 89,990Source | 354,860Source | 181,729Source | 360,594Source | 213,238Source | 1,256,856Source | 361,800Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss) | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Net Income (Loss) Attributable to Parent | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Interest Income, Other | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Costs and Expenses | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
Offerings
Registration 333-294461
Registration 333-294461-01
Filing attachments
nybholdingslimited_ex99-2.htm · F-4/A · 2026-06-16
Exhibit 99.2 June 16, 2026 NYB Holdings Limited (the “Company”) 456 Alexandra Road. #04-07Fragrance Empire BuildingSingapore 119962 Ladies and Gentlemen: Pursuant to Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the references to my name in the Registration Statement on Form F-4 (the “Registration Statement”) of the Company and any amendments thereto, which indicate that I have accepted the appointment to become a director of the Company. I also consent to the f…
Read attachment ↗nybholdingslimited_ex99-2.htm · F-4/A · 2026-06-03
Exhibit 99.2 May 29, 2026 NYB Holdings Limited (the “Company”) 456 Alexandra Road. #04-07Fragrance Empire BuildingSingapore 119962 Ladies and Gentlemen: Pursuant to Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the references to my name in the Registration Statement on Form F-4 (the “Registration Statement”) of the Company and any amendments thereto, which indicate that I have accepted the nomination to become a director of the Company. I also consent to the fil…
Read attachment ↗nybholdingslimited_ex99-1.htm · F-4/A · 2026-05-05
Exhibit 99.1 PROXY CARD FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF RF ACQUISITION CORP II THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Tse Meng Ng, the Company’s Chief Executive Officer, as proxy (the “Proxy”), with the power to appoint a substitute to vote the shares that the undersigned is entitled to vote (the “Shares”) at the Extraordinary General Meeting of shareholders of RF Acquisition Corp II (the “Company”) to be held on [●…
Read attachment ↗rfacquisition2_ex99-1.htm · 8-K · 2025-10-02
EX-99.1 5 rfacquisition2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II In US$1.5B Transaction to Pursue Public Listing Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the “Company”, “we” or “NYB”), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. Patented F…
Read attachment ↗